Morphoceuticals raises $8M to advance bioelectrical treatment for regenerating tissues or organs
Longevity Technology - 15-Feb-2023A revolutionary approach in regenerative medicine that could improve quality of life in patients
Join the club for FREE to access the whole archive and other member benefits.
Professor, CMO of e-Nicotine Technology and CEO of LyGenesis.
Dr. Hufford is the Chief Medical Officer and a co-founder of e-Nicotine Technology. He has 16 years of experience in nicotine research, drug development, and entrepreneurship. Dr. Hufford’s drug development experience includes serving as Vice President of Corporate and Clinical Development at Cypress Bioscience, where his responsibilities included drug and medical device development in support of multiple CNS assets, including the clinical development and FDA approval of Savella® (milnacipran) for fibromyalgia.
Dr. Hufford earned his Bachelor’s Degree with Distinction in Psychology from Purdue University, and his Master’s and Doctoral degrees in Clinical Psychology from the University of Pittsburgh, where his research focused on smoking and other addictive behaviors. He completed his clinical internship at the McLean Hospital, where he was a Clinical and Research Fellow in the Department of Psychiatry at Harvard Medical School.
Visit website: http://enicotinetechnology.com/team/michael-hufford-phd/
See also: LyGenesis - Organ regeneration using a patient's lymph nodes as bioreactors to grow ectopic organs
Details last updated 23-Oct-2019
26-Feb-2022 to 27-Feb-2022
Event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX)
A revolutionary approach in regenerative medicine that could improve quality of life in patients
Raised $11M funding which goes into trials and developing functional organs
Takes us a step ahead towards regenerating organs for human diseases
LyGenesis is developing a technique for implanting cells into lymph nodes for future transplantation